E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pulmonary arterial hypertension |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10036727 |
E.1.2 | Term | Primary pulmonary hypertension |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is: To assess efficacy on pulmonary artery pressure after 15 weeks of therapy compared to baseline by comparison of the pulmonary vascular resistance.
|
|
E.2.2 | Secondary objectives of the trial |
The secondary objective of the study is: To assess clinical, haemodynamic, respiratory, functional and cardiovascular parameters following treatment with Terguride (dosage between 1,5 mg/day min and 3,0 mg/day max) after 15 weeks To assess efficacy and tolerability of Terguride in the treatment of patients with PAH compared to placebo for 15 weeks. To assess safety of Terguride in comparison to placebo over a period of time of 15 weeks.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Female and male patients of any racial origin with PAH (WHO classification II-IV) 2. On stable treatment with best supportive care with anticoagulant drugs, diuretics, cardiac glycosides, supplemental oxygen and calcium channels blockers, adjusted to the individual need of the respective patient. Specific PAH mono-therapy (or combination-therapy not exceeding two PAH specific drugs) with either endothelin receptor antagonists or phosphodiesterase type 5 inhibitors or non-parenteral prostanoids (i.e. inhaled, oral, s.c.) is allowed (pre-treated patients) but not mandatory (treatment naive patients). Patients already on PAH specific drugs must be receiving a stable dose of the medication for at least 3 months 3. Having fulfilled his/her 18th birthday on Day 1 of the study but not older than 80 years (up to the patient’s 81st birthday). 4. PAH due to idiopathic pulmonary arterial hypertension or connective tissue disease associated PAH 5. Cardiac catheterisation 4 weeks prior to screening or at screening with PAH, specifically PAPm >=25 mmHg (at rest), Pulmonary capillary wedge pressure (PCWP) <=16 mmHg, pulmonary vascular resistance >=500 dyn x sec x cm-5. Echocardiogram at screening consistent with PAH, specifically evidence of right ventricular hypertrophy or dilation, evidence of normal left ventricular function, and absence of mitral valve stenosis 6. Six minute walk distance above 150 m 7. Receiving conventional PAH therapy, stable for one month. 8. Presentation of negative test results in regard to HIV, Hepatitis C/B, not older than 4 weeks. 9. Able to understand and willing to sign the Informed Consent Form.
|
|
E.4 | Principal exclusion criteria |
1. Pregnancy and/or lactation 2. PAH of any cause other than permitted in the entry criteria 3. Contraindication for heart catheterisation 4. Any change in disease-targeted therapy within the last month before screening 5. Patients requiring intravenous prostanoid therapy within 3 months prior to study start 6. Any subject who had received any investigational medication within 1 month prior to the start of this study or who is scheduled to receive another investigational drug during the course of this study 7. Known intolerance to Terguride 8. Active liver disease, porphyria or elevations of serums transaminases >3 x ULN (upper limit of normal) or bilirubin > 1.5 x ULN 9. History or suspicion of inability to cooperate adequately . 10. Cancer or other malign haematological disease 11. Pulmonary Hypertension caused by left heart disease 12. Pulmonary Arterial Hypertension associated with congenital heart disease (PAH-CHD) 13. Pulmonary Arterial Hypertension associated with human immunodeficiency virus infection (PAH-HIV) 14. Portopulmonary Hypertension (PPHT) 15. CTEPH Chronic Thromboembolic Pulmonary Hypertension 16. Pulmonary Hypertension associated with other diseases (i.e. Sarcoidosis, Histiocytosis, etc) 17. Pulmonary Hypertension associated with other chronic lung diseases
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint for this investigation is: Pulmonary vascular resistance at final cardiac catheterisation (15 weeks from initial cardiac catheterisation) as objective measure Benchmark: significant reduction (20% vs. baseline) of pulmonary vascular resistance
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 22 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 0 |